Flixonase spray nasal dosage. 50mkg / dose 60 doses

Amount in a package

60 doses

Dosage form

nasal spray

Appointment

Antiallergic

Manufacturer

GlaxoSmithKline, Spain

Structure

Active ingredient: fluticasone propionate (micronized) 50 mcg

Excipients: anhydrous dextrose, microcrystalline cellulose, microcrystalline carboxymethyl cellulose, phenylethyl alcohol, benzalkonium chloride solution, polysorbate 80, diluted hydrochloric acid, purified water.

pharmachologic effect

FLIXONASE - anti-allergic, decongestant, anti-inflammatory.

The anti-inflammatory effect is realized as a result of the interaction of the drug with the GCS receptors.

Suppresses the proliferation of mast cells, eosinophils, lymphocytes, macrophages, neutrophils.

Fluticasone propionate reduces the production of inflammatory mediators and other biologically active substances (histamine, PG, leukotrienes, cytokines) during the early and late phases of an allergic reaction.

Restores the patient's reaction to bronchodilators, allowing to reduce the frequency of their use.

Reduces sneezing, itchy nose, runny nose, nasal congestion, sinus discomfort and pressure around the nose and eyes.

In addition, it relieves eye symptoms associated with allergic rhinitis.

Pharmacodynamics

It has a fast anti-inflammatory effect on the nasal mucosa, and its antiallergic effect appears within 2-4 hours after the first application.

A decrease in the severity of symptoms (especially nasal congestion) persists for 24 hours after a single injection of a spray at a dose of 200 μg.

Fluticasone propionate improves patients' quality of life, including physical and social activity.

When used in the recommended doses, it does not have any pronounced systemic activity and practically does not inhibit the hypothalamic-pituitary-adrenal system.

Pharmacokinetics

After intranasal administration of fluticasone propionate (200 μg / day), Cmax in plasma is not detected in most patients (i.e., it is less than 0.01 ng / ml). The highest Cmax is 0.017 ng / ml. Direct absorption on the nasal mucosa is negligible due to the low solubility of the drug in water, as a result of which most of the dose is ultimately swallowed. Less than 1% of the dose is absorbed from the gastrointestinal tract into the bloodstream due to poor absorption and presystemic metabolism. All this leads to the fact that the total absorption in the nasal cavity and the gastrointestinal tract (swallowed drug) is extremely low. When the equilibrium plasma concentration is reached, fluticasone propionate has a large volume of distribution (about 318 liters). It has a fairly high ability to bind to plasma proteins (91%).

Fluticasone propionate is rapidly excreted from plasma, mainly as a result of metabolism in the liver to an inactive carboxylic metabolite under the action of the cytochrome P450 isoenzyme CYP3A4.

Swallowed fluticasone propionate is extensively metabolized as a result of its primary passage through the liver.

The main route of elimination is the excretion of fluticasone propionate and its metabolites in the bile.

Indications

Regular therapy of bronchial asthma

allergic rhinitis, eczema

psoriasis

neurodermatitis.

Contraindications

Hypersensitivity to Fliksonase.

Side effects

Local reactions: dryness and irritation of the nasopharynx, unpleasant taste and smell, nosebleeds, burning sensation, nasal congestion

very rarely (less than 1/10 000 cases) - perforation of the nasal septum (especially with a history of surgical interventions in the nasal cavity).

Allergic reactions: possible skin rash, swelling of the face and tongue

very rarely (less than 1/10 000 cases) - anaphylactic reactions and bronchospasm.

Others: headache.

Very rare cases of glaucoma, increased intraocular pressure and cataracts have been reported.

Name ENG

FLIXONASE

Clinical and pharmacological group

GCS for intranasal use

ATX code

Fluticasone

Dosage

50mcg / dose x 60dose

Structure

Active ingredient: fluticasone propionate (micronized) 50 mcg

Excipients: anhydrous dextrose, microcrystalline cellulose, microcrystalline carboxymethyl cellulose, phenylethyl alcohol, benzalkonium chloride solution, polysorbate 80, diluted hydrochloric acid, purified water.

Indications

Seasonal and perennial allergic rhinitis (prevention and treatment).

Storage conditions and periods

At a temperature not higher than 30 degrees.

Expiration date: 3 years

INN / Active ingredient

Fluticasone

Specifications

Category

Runny nose

Scope of the medicinal product

Ear, Throat, Nose

Release form

Spray

Manufacturer country

Spain

Package quantity, pcs

one

Scope of application

Allergology

Minimum age from

4 years old

Way of introduction

Intranasally

Vacation conditions

Without recipe

Brand name

Fliksonase

The amount of the dosage form in the primary package

60 dose

Primary packaging type

Bottle

Type of consumer packaging

Pack of cardboard

Pharmaco-therapeutic group

Topical glucocorticosteroid

Anatomical and therapeutic characteristics

R01AD08 Fluticasone

Dosage form

Dosed nasal spray

Expiration date in days

1095

Dosage (volume) of the substance in the preparation

fluticasone propionate (micronized) - 50 mcg

The target audience

Children

Package weight, g

twenty

Mode of application

:

Flixonase is intended for intranasal use only. To achieve the full therapeutic effect, the drug should be used regularly. < br> For the prevention and treatment of seasonal allergic rhinitis and perennial allergic rhinitis, adults and children over 12 years of age are prescribed 100 μg (2 doses) in each nostril 1 time / day (total dose 200 μg / day), preferably in the morning. After symptom control is achieved, 50 μg (1 dose) can be administered to each nostril 1 time / day (total dose 100 μg / day). < br> In some cases, it is required to apply 100 mcg (2 doses) in each nostril 2 times / day (total dose 400 mcg / day) for a short time in order to achieve control of symptoms, after which the dose can be reduced. The maximum daily dose of the drug is 400 mcg (4 doses in each nostril). < br> Elderly patients do not require dosage adjustment. < br> For children aged 4-12 years for the prevention and treatment of seasonal allergic rhinitis, it is recommended to prescribe 50 mcg (1 dose) in each nostril 1 time / day. The maximum daily dose of the drug is 200 mcg (2 doses in each nostril). < br> The maximum therapeutic effect appears after 3-4 days of therapy. To achieve the full therapeutic effect, the drug must be used regularly.The maximum therapeutic effect is manifested after 3-4 days of therapy. To achieve the full therapeutic effect, the drug must be used regularly.The maximum therapeutic effect is manifested after 3-4 days of therapy. To achieve the full therapeutic effect, the drug must be used regularly.

Information on technical characteristics, delivery set, country of manufacture